From GlobeNewswire: 2024-06-04 16:01:00

Fate Therapeutics, Inc. grants a non-qualified stock option to one newly-hired employee for 65,000 shares of common stock and restricted stock units (RSUs) representing 14,500 shares to three new non-executive employees. The option will vest over four years, with 25% vesting on the one-year anniversary and the RSUs will also vest over four years with 25% vesting on each anniversary of the grant date. Fate Therapeutics’ iPSC platform allows mass production of engineered cell products for cancer and autoimmune disorders. The company holds over 400 issued patents and 450 pending patent applications to support their product platform.



Read more at GlobeNewswire: Fate Therapeutics Reports New Employee Inducement Awards